SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $136,099,277 |
| Positions | 41 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| ACADIA PHARMACEUTICALS INC | ACAD | COM | $10,373,000 | 410,000 |
| XERIS BIOPHARMA HOLDINGS INC | XERS | COM | $9,741,600 | 1,230,000 |
| BIOMARIN PHARMACEUTICAL INC | BMRN | COM | $8,211,070 | 143,500 |
| PRAXIS PRECISION MEDICINES I | PRAX | COM NEW | $7,549,515 | 22,550 |
| ULTRAGENYX PHARMACEUTICAL IN | RARE | COM | $6,844,950 | 205,000 |
| AGIOS PHARMACEUTICALS INC | AGIO | COM | $6,086,040 | 164,000 |
| INSMED INC | INSM | COM PAR $.01 | $5,464,275 | 51,250 |
| CRINETICS PHARMACEUTICALS IN | CRNX | COM | $5,369,770 | 143,500 |
| ZENTALIS PHARMACEUTICALS INC | ZNTL | COM | $4,971,250 | 1,025,000 |
| VAXCYTE INC | PCVX | COM | $4,766,660 | 82,000 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.